Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Rhea-AI Summary
Instil Bio (Nasdaq: TIL) reported second quarter 2026 results, highlighting ongoing evaluation of potential acquisitions and in-licensing opportunities for novel therapeutics and a strong cash runway. As of June 30, 2026, cash, cash equivalents, restricted cash and marketable securities totaled $69.9 million, down from $76.3 million at December 31, 2025, which the company expects will fund its operating plan beyond 2027.
For Q2 2026, total operating expenses were $5.6 million, compared with $23.4 million in Q2 2025, reflecting sharp reductions in in-process R&D, R&D and restructuring charges. Net loss was $4.3 million, or $0.63 per share, versus $21.4 million, or $3.24 per share, a year earlier. Non-GAAP net loss was $3.1 million, or $0.45 per share, compared with $19.0 million, or $2.88 per share, in Q2 2025.
Positive
- Cash and securities $69.9 million at June 30, 2026, with runway beyond 2027
- Total operating expenses $5.6 million in Q2 2026 vs. $23.4 million in Q2 2025
- Net loss $4.3 million in Q2 2026 vs. $21.4 million in Q2 2025
- Non-GAAP net loss $3.1 million in Q2 2026 vs. $19.0 million in Q2 2025
- Restructuring and impairment charges fell to $0.2 million in Q2 2026 from $0.5 million
- Other rental income $2.2 million in Q2 2026 and $4.5 million for six months 2026
Negative
- Cash and securities decreased to $69.9 million from $76.3 million since December 31, 2025
- Net loss $8.5 million for six months 2026, despite reductions from $49.6 million in 2025
- Interest expense $1.6 million in Q2 2026 and $3.1 million for six months 2026
- Total liabilities $90.3 million at June 30, 2026, slightly above $89.7 million at year-end 2025
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | First-quarter earnings | Positive | +0.3% | Lower expenses and cash runway beyond 2027 accompanied the quarterly report. |
| Mar 27 | Full-year earnings | Negative | -6.8% | Pipeline restructuring followed discontinuation of AXN-2510 development. |
| Nov 13 | Third-quarter earnings | Negative | -7.2% | Cash declined while quarterly and nine-month per-share losses remained substantial. |
| Aug 13 | Second-quarter earnings | Positive | +0.5% | FDA clearance and pipeline progress accompanied the financial update. |
| May 13 | First-quarter earnings | Negative | -6.9% | Restructuring charges increased alongside a higher reported per-share loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-tag reactions were mixed, with 2 aligned gains and 3 divergences; the five-event average was -4.01%.
Key Terms
gaap financial
non-gaap financial measures financial
marketable securities financial
stock-based compensation expense financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and provided a corporate update.
Recent Highlights:
- Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic candidates.
- Cash position of approximately
$69.9 million as of June 30, 2026 expected to fund current operating plan beyond 2027.
Second Quarter 2026 Financial and Operating Results:
As of June 30, 2026, Instil had cash, cash equivalents, restricted cash and marketable securities of
In-process research and development expenses were nil for the three and six months ended June 30, 2026, compared to
Research and development expenses were
General and administrative expenses were
Restructuring and impairment charges were
Net loss per share, basic and diluted were
Note Regarding Use of Non-GAAP Financial Measures
In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil’s financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil’s operating results. In addition, these non-GAAP financial measures are among the indicators Instil’s management uses for planning purposes and to measure Instil’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.
About Instil Bio
Instil Bio, Inc. is a biotechnology company focused on identifying and advancing innovative therapeutics. For more information, visit www.instilbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “exploring,” “evaluating,” “focused,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” “targets,” and “will” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements concerning Instil’s expectations regarding pursuing potential acquisitions, in-licensing and related opportunities; Instil’s expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties related to pursuing potential transactions to acquire companies or equity interests therein or in-license product candidates, and the sufficiency of Instil’s cash resources, as well as interest rates, inflation and other factors which could materially and adversely affect Instil’s business and operations, and other risks and uncertainties affecting Instil’s plans and strategy, including those discussed in the section titled “Risk Factors” in Instil’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the SEC and Instil’s Annual Report on Form 10-K for the year ended December 31, 2025 filed on March 27, 2026, as well as Instil’s other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.
Contacts:
Investor Relations:
1-972-499-3350
investorrelations@instilbio.com
www.instilbio.com
| INSTIL BIO, INC. SELECTED FINANCIAL DATA | |||||
| Selected Condensed Consolidated Balance Sheet Data (Unaudited; in thousands) | |||||
| June 30, 2026 | December 31, 2025 | ||||
| Cash, cash equivalents, restricted cash and marketable securities | $ | 69,932 | $ | 76,295 | |
| Total assets | $ | 197,712 | $ | 203,523 | |
| Total liabilities | $ | 90,332 | $ | 89,657 | |
| Total stockholders’ equity | $ | 107,380 | $ | 113,866 | |
| Condensed Consolidated Statements of Operations (Unaudited; in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||
| June 30, | June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses: | |||||||||||||||
| In-process research and development | $ | — | $ | 10,000 | $ | — | $ | 10,000 | |||||||
| Research and development | 270 | 6,743 | 939 | 12,114 | |||||||||||
| General and administrative | 5,130 | 6,157 | 10,479 | 15,266 | |||||||||||
| Restructuring and impairment charges, net | 181 | 540 | 1,173 | 16,622 | |||||||||||
| Total operating expenses | 5,581 | 23,440 | 12,591 | 54,002 | |||||||||||
| Loss from operations | (5,581 | ) | (23,440 | ) | (12,591 | ) | (54,002 | ) | |||||||
| Interest income | 632 | 1,044 | 1,310 | 2,219 | |||||||||||
| Interest expense | (1,582 | ) | (1,582 | ) | (3,134 | ) | (2,680 | ) | |||||||
| Other rental income | 2,242 | 2,242 | 4,484 | 4,484 | |||||||||||
| Gain on contract termination | — | — | 1,620 | — | |||||||||||
| Other (expense) income, net | (10 | ) | 342 | (192 | ) | 385 | |||||||||
| Net loss | $ | (4,299 | ) | $ | (21,394 | ) | $ | (8,503 | ) | $ | (49,594 | ) | |||
| Net loss per share, basic and diluted | $ | (0.63 | ) | $ | (3.24 | ) | $ | (1.25 | ) | $ | (7.55 | ) | |||
| Weighted-average shares used in computing net loss per share, basic and diluted | 6,781,976 | 6,596,975 | 6,781,976 | 6,564,994 | |||||||||||
| INSTIL BIO, INC. Reconciliation of GAAP to Non-GAAP Net Loss and Net Loss per Share (Unaudited; in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||
| June 30, | June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net loss | $ | (4,299 | ) | $ | (21,394 | ) | $ | (8,503 | ) | $ | (49,594 | ) | |||
| Adjustments: | |||||||||||||||
| Non-cash stock-based compensation expense | 1,036 | 1,824 | 2,021 | 5,319 | |||||||||||
| Restructuring and impairment charges | 181 | 540 | 1,173 | 16,622 | |||||||||||
| Non-GAAP net loss | $ | (3,082 | ) | $ | (19,030 | ) | $ | (5,309 | ) | $ | (27,653 | ) | |||
| Net loss per share, basic and diluted | $ | (0.63 | ) | $ | (3.24 | ) | $ | (1.25 | ) | $ | (7.55 | ) | |||
| Adjustments: | |||||||||||||||
| Non-cash stock-based compensation expense per share | 0.15 | 0.28 | 0.30 | 0.81 | |||||||||||
| Restructuring and impairment charges per share | 0.03 | 0.08 | 0.17 | 2.53 | |||||||||||
| Non-GAAP net loss per share, basic and diluted* | $ | (0.45 | ) | $ | (2.88 | ) | $ | (0.78 | ) | $ | (4.21 | ) | |||
| Weighted-average shares outstanding, basic and diluted | 6,781,976 | 6,596,975 | 6,781,976 | 6,564,994 | |||||||||||
* Non-GAAP net loss per share, basic and diluted may not total due to rounding.
